Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Nov;10(11):2106-2116.
doi: 10.1111/1759-7714.13189. Epub 2019 Sep 10.

Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases

Yu Saida  1 , Satoshi Watanabe  1 , Tetsuya Abe  2 , Satoshi Shoji  1 , Koichiro Nozaki  1 , Kosuke Ichikawa  1 , Rie Kondo  1 , Kenichi Koyama  3 , Satoru Miura  3 , Hiroshi Tanaka  3 , Masaaki Okajima  4 , Masaki Terada  4 , Takashi Ishida  5 , Hiroki Tsukada  6 , Masato Makino  7 , Akira Iwashima  8 , Kazuhiro Sato  9 , Naoya Matsumoto  10 , Hirohisa Yoshizawa  1   11 , Toshiaki Kikuchi  1
Affiliations
Comparative Study

Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases

Yu Saida et al. Thorac Cancer. 2019 Nov.

Abstract

Background: Although the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) patients has been demonstrated, their efficacy in EGFR-mutant NSCLCs with central nervous system (CNS) metastases and the role of radiotherapy remain unclear. This study aimed to determine if it is preferable to add upfront cranial radiotherapy to EGFR-TKIs in patients with EGFR-mutant NSCLC with newly diagnosed brain metastases.

Methods: We retrospectively analyzed the data of EGFR-mutant NSCLC patients with CNS metastases who received EGFR-TKIs as a first-line therapy.

Results: A total of 104 patients were enrolled and 39 patients received upfront brain radiotherapy, while 65 patients received first and second generation EGFR-TKIs first. The median time to treatment failure (TTF) was 7.8 months (95% confidence interval [CI]: 6.3-9.4). The median survival time (MST) was 24.0 months (95% CI: 20.1-30.1). The overall response rate of the CNS was 37%. The median CNS progression-free survival (PFS) was 13.2 months (95% CI: 10.0-16.2). Brain radiotherapy prior to EGFR-TKI prolonged TTF (11.2 vs. 6.8 months, P = 0.038) and tended to prolong CNS-PFS (15.6 vs. 11.1 months, P = 0.096) but was not significantly associated with overall survival (MST 26.1 vs. 24.0 months, P = 0.525). Univariate and multivariate analyses indicated that poor performance status and the presence of extracranial metastases were poor prognostic factors related to overall survival.

Conclusion: EGFR-TKI showed a favorable effect for EGFR-mutant NSCLC patients with CNS metastases. Prolonged TTF and CNS-PFS were observed with upfront brain radiotherapy.

Keywords: EGFR mutation; Brain metastases; EGFR tyrosine kinase inhibitor; non-small cell lung cancer; radiotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan‐Meier analysis of time to treatment failure, CNS‐PFS, and overall survival in the entire population (a, b, and c). Kaplan‐Meier analysis of time to treatment failure, CNS‐PFS, and overall survival compared between patients treated with upfront brain radiotherapy (RT) and those treated without upfront RT (d, e, and f). CI, confidence interval; CNS, central nervous system; PFS, progression‐free survival. formula image 1st RT and formula image 1st TKI.
See this image and copyright information in PMC

References

    1. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005; 23: 6207–19. - PubMed
    1. Komaki R, Cox JD, Stark R. Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: Correlation with survival. Int J Radiat Oncol Biol Phys 1983; 9: 1467–70. - PubMed
    1. Sørensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: Frequency, risk groups, and prognosis. J Clin Oncol 1988; 6: 1474–80. - PubMed
    1. Iuchi T, Shingyoji M, Itakura M et al Frequency of brain metastases in non‐small‐cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol 2015; 20: 674–9. - PubMed
    1. Mitsudomi T, Morita S, Yatabe Y et al Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8. - PubMed

Publication types

MeSH terms